» Articles » PMID: 39200090

Infection Prevention and Control Strategies According to the Type of Multidrug-Resistant Bacteria and in Intensive Care Units: A Pragmatic Resume Including Pathogens R and a Cost-Effectiveness Analysis

Overview
Specialty Pharmacology
Date 2024 Aug 29
PMID 39200090
Authors
Affiliations
Soon will be listed here.
Abstract

Multidrug-resistant organism (MDRO) outbreaks have been steadily increasing in intensive care units (ICUs). Still, healthcare institutions and workers (HCWs) have not reached unanimity on how and when to implement infection prevention and control (IPC) strategies. We aimed to provide a pragmatic physician practice-oriented resume of strategies towards different MDRO outbreaks in ICUs. We performed a narrative review on IPC in ICUs, investigating patient-to-staff ratios; education, isolation, decolonization, screening, and hygiene practices; outbreak reporting; cost-effectiveness; reproduction numbers (R); and future perspectives. The most effective IPC strategy remains unknown. Most studies focus on a specific pathogen or disease, making the clinician lose sight of the big picture. IPC strategies have proven their cost-effectiveness regardless of typology, country, and pathogen. A standardized, universal, pragmatic protocol for HCW education should be elaborated. Likewise, the elaboration of a rapid outbreak recognition tool (i.e., an easy-to-use mathematical model) would improve early diagnosis and prevent spreading. Further studies are needed to express views in favor or against MDRO decolonization. New promising strategies are emerging and need to be tested in the field. The lack of IPC strategy application has made and still makes ICUs major MDRO reservoirs in the community. In a not-too-distant future, genetic engineering and phage therapies could represent a plot twist in MDRO IPC strategies.

Citing Articles

Tracheal tube infections in critical care: A narrative review of influencing factors, microbial agents, and mitigation strategies in intensive care unit settings.

Motallebirad T, Mohammadi M, Jadidi A, Safarabadi M, Kerami A, Azadi D SAGE Open Med. 2024; 12:20503121241306951.

PMID: 39691863 PMC: 11650591. DOI: 10.1177/20503121241306951.


Study on the predictive value of APACHE II score and neurogenic dysphagia in carbapenem-resistant Klebsiella pneumoniae.

Zhou X, Zhang Z, Wang X, Wang Y Medicine (Baltimore). 2024; 103(50):e40858.

PMID: 39686489 PMC: 11651494. DOI: 10.1097/MD.0000000000040858.

References
1.
Seah V, Ong R, Lim A, Chong C, Tan N, Thoon K . Impact of a Carbapenem Antimicrobial Stewardship Program on Patient Outcomes. Antimicrob Agents Chemother. 2017; 61(9). PMC: 5571328. DOI: 10.1128/AAC.00736-17. View

2.
Gray A, Allard R, Pare R, Tannenbaum T, Lefebvre B, Levesque S . Management of a hospital outbreak of extensively drug-resistant Acinetobacter baumannii using a multimodal intervention including daily chlorhexidine baths. J Hosp Infect. 2016; 93(1):29-34. DOI: 10.1016/j.jhin.2015.12.013. View

3.
Steinig E, Aglua I, Duchene S, Meehan M, Yoannes M, Firth C . Phylodynamic signatures in the emergence of community-associated MRSA. Proc Natl Acad Sci U S A. 2022; 119(45):e2204993119. PMC: 9659408. DOI: 10.1073/pnas.2204993119. View

4.
Hoenigl M, Salmanton-Garcia J, Walsh T, Nucci M, Neoh C, Jenks J . Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for.... Lancet Infect Dis. 2021; 21(8):e246-e257. DOI: 10.1016/S1473-3099(20)30784-2. View

5.
Oren I, Sprecher H, Finkelstein R, Hadad S, Neuberger A, Hussein K . Eradication of carbapenem-resistant Enterobacteriaceae gastrointestinal colonization with nonabsorbable oral antibiotic treatment: A prospective controlled trial. Am J Infect Control. 2013; 41(12):1167-72. DOI: 10.1016/j.ajic.2013.04.018. View